Volkmar Müller

Jun 18, 2024 | preprints.org | Volkmar Müller

PreprintArticleVersion 1This version is not peer-reviewedVersion 1: Received: 15 June 2024 / Approved: 18 June 2024 / Online: 18 June 2024 (09:42:58 CEST)Müller, V. Cosmic Expansion – Clues From the Earth. Preprints 2024, 2024061202. https://doi.org/10.20944/preprints202406.1202.v1Müller, V. Cosmic Expansion – Clues From the Earth. Preprints 2024, 2024061202. https://doi.org/10.20944/preprints202406.1202.v1 Export citation file:Bib TeX|RISMDPI and ACS StyleMüller, V.

Jun 3, 2024 | high5oncology.tv | Valentina Guarneri |Diana Lüftner |Alessandra Gennari |Volkmar Müller

Breast cancer early - 100 seconds ENG Breast cancer early - 100 seconds multi language Breast cancer metastatic - 100 seconds ENG Endocrine therapy with Palbociclib + Trastuzumab Chemo-free regimen in HER2+ luminal breast cancer Systemic therapy of HER2+ patients with brain metastases Leptomeningeal metastases in HER2+ mBC Novel ADC-ICI combination therapy HER2+ mBC 1stL T-Dxd Low ER-receptor: endocrine therapy necessary after all? Broaden T-DXD as therapy standard for HER2low and ultra-low...

Dec 5, 2023 | emjreviews.com | Antonio Llombart-Cussac |Virginia Kaklamani |Volkmar Müller

Introduction Over 70% of breast cancers are ER+/HER2-, for which the backbone of treatment is endocrine therapy.1-3 Endocrine therapies for ER+/HER2- advanced breast cancer at 1L include aromatase inhibitors, such as anastrozole, letrozole, and exemestane; selective oestrogen receptor modulators, such as tamoxifen; and SERDs, such as fulvestrant.4 Antonio Llombart-Cussac, Head of Medical Oncology at the Arnau de Vilanova Hospital in Valencia, Spain, emphasised that the addition of CDK4/6...